Guided Therapeutics (GTHP) Interest Expenses (2010 - 2025)

Guided Therapeutics has disclosed Interest Expenses across 16 years of filings, most recently posting $184000.0 for Q4 2025.

• Interest Expenses for Q4 2025 came in at $184000.0, up 37.31% year-over-year; the trailing twelve-month figure through Dec 2025 was $617000.0 (up 61.94% YoY), and the FY2025 annual result was $617000.0, up 61.94% from the prior year.
• Interest Expenses came in at $184000.0 for Q4 2025 at Guided Therapeutics, up from $129000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $594000.0 in Q3 2021 to a low of $64000.0 in Q1 2024.
• The 5-year median for Interest Expenses is $118500.0 (2024), against an average of $150400.0.
• Across the five-year window, Interest Expenses sank 73.91% in 2022 and jumped 129.69% in 2025, its largest moves.
• Guided Therapeutics' Interest Expenses stood at $100000.0 in 2021, then dropped by 30.0% to $70000.0 in 2022, then advanced by 2.86% to $72000.0 in 2023, then jumped by 86.11% to $134000.0 in 2024, then jumped by 37.31% to $184000.0 in 2025.
• The last three Interest Expenses figures came in at $184000.0 (Q4 2025), $129000.0 (Q3 2025), and $157000.0 (Q2 2025), per Business Quant data.